CC2D1B

Across TCGA pan-cancer cohorts, CC2D1B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CC2D1B data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CC2D1B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CC2D1B expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where CC2D1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.977	0.451	.001	24	view →
COAD	DFS	Tertile	II,III,IV	0.911	1.000	.036	12	view →
CCRCC	DFS	Tertile	II,III,IV	0.222	0.972	.013	8	view →
HNSC	OS	Median	All	0.906	0.799	.007	7	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	2	view →
LUAD	DFS	Tertile	II,III,IV	0.607	0.320	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CC2D1B–PDAC (DFS)

Open the PDAC breakdown →